XAGE (Longevity Health Holdings) Research & Development: $0.62 Mil (TTM As of Mar. 2026)


XAGE Longevity Health Holdings Inc XAGE
6 GF Score
Price $0.26
! 3 Warning Signs
View Full Analysis

What is Longevity Health Holdings Research & Development?

Longevity Health Holdings XAGE -23.30% 6 Research & Development is $0.62 Mil as of Mar. 2026. GuruFocus rates XAGE with a GF Score™ of 6/100. The stock has 3 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Longevity Health Holdings's Research & Development for the three months ended in Mar. 2026 was $0.06 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $0.62 Mil.

Longevity Health Holdings  (OTCPK:XAGE) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Longevity Health Holdings Research & Development Related Terms

Longevity Health Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Longevity Health Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Health Holdings Research & Development Chart

Longevity Health Holdings Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
0.98 2.20 2.50 1.05 0.79

Longevity Health Holdings Quarterly Data
Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.20 0.23 0.23 0.10 0.06
XAGE
6GF Score
Longevity Health Holdings Inc XAGE
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Longevity Health Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.62 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.62 Mil mean?
Longevity Health Holdings (XAGE) has a Research & Development of $0.62 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Longevity Health Holdings and its competitors.
Is Longevity Health Holdings' Research & Development too high?
Longevity Health Holdings' current Research & Development is $0.62 Mil. Overall, Longevity Health Holdings has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Longevity Health Holdings' Research & Development compare to SNBH and SKVI?
Longevity Health Holdings' Research & Development of $0.62 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Consumer Packaged Goods company?
A good Research & Development depends on the Consumer Packaged Goods industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Longevity Health Holdings and its competitors. Longevity Health Holdings's current Research & Development is $0.62 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Longevity Health Holdings stock overvalued right now?
Longevity Health Holdings (XAGE) has a current Research & Development of $0.62 Mil. The current Research & Development is $0.62 Mil. Longevity Health Holdings' overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Longevity Health Holdings (XAGE), the current Research & Development is $0.62 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Longevity Health Holdings Business Description

Address 2403 Sidney Street, Suite 300, Pittsburgh, PA, USA, 15203
Longevity Health Holdings Inc is a bio-aesthetics company focused on longevity and healthy aging. The company develops cosmetic skincare and haircare products designed to support skin and hair health, tailored to meet the technical requirements of professional care providers as well as retail consumers. Its product pipeline also includes regenerative bone and tissue healing solutions, although further research and development in this area has been paused. The company markets its cosmetic products in the United States through business-to-business, direct-to-consumer, and distributor sales channels.
6GF Score

Get the complete analysis for XAGE

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.26
Price